The Phase One Foundation has awarded GIST Specialist Jason Sicklick a $500,000 grant to study GIST in a Temozolomide Phase II clinical trial.
Partnerships and collaborations are critical to the progress of research in rare diseases. GIST specialist & Pediatric & SDH-Deficient GIST Consortium member, Dr. Jason Sicklick, and LRG member, Debra Melikian, are working together find a cure for succinate dehydrogenase-deficient gastrointestinal stromal tumors (SDH-deficient GIST), a hereditary rare cancer syndrome which claimed the lives of Debra’s husband and her son Merak.
Deb Melikian, patient advocate, and Dr. Jason Sicklick, GIST expert & researcher, share the story of their unique partnership which began at an LRG GIST Day of Learning in the rare partners issue of RARE Revolution Magazine.
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.
A Pediatric & SDH-Deficient GIST Consortium Update: A Review with Experts & Advocates presented by Jayne Bressington, Becky Owens, and Dr. Jason Sicklick at New Horizons 2019 in Wayne, NJ.
Rare GIST Sub-Types presented by Dr. Jason Sicklick of Moores UCSD Cancer Center at New Horizons 2019 in Wayne, NJ.
Understanding the Concept of "Precision Oncology" in patient-friendly language presented by Dr. Jason Sicklick of Moores Cancer Center UCSD at New Horizons 2019.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Julie Durkee shares her story.
GIST experts provided updates and answered questions on GIST research and new GIST therapies.
When facing a diagnosis of cancer, self-advocacy becomes an important survival skill for patients and caregivers. These stories illustrate what an ordinary person can accomplish due to extraordinary circumstances and how they affected change for so many people with GIST.